Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler

J Bousquet, A D'Urzo, J Hebert, CH Barraza, LP Boulet, R Suarez-Chacon, U Harnest, B Lundback, G Martinez Morales, MM Nieminen, KB Nolop, S Visser, BN Lutsky
European Respiratory Journal 2000 16: 808-816; DOI:
J Bousquet
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A D'Urzo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J Hebert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CH Barraza
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LP Boulet
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R Suarez-Chacon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
U Harnest
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B Lundback
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G Martinez Morales
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MM Nieminen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KB Nolop
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S Visser
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BN Lutsky
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Mometasone furoate (MF) administered by dry powder inhaler (DPI) was composed with budesonide (BUD) Turbuhaler in the treatment of moderate persistent asthma. The patients were randomized to one of four treatment groups: MF DPI (100, 200, 400 microg b.i.d) or BUD Turbuhaler. 400 microg b.i.d in a 12-week, active-controlled, evaluator-blind, multicentre international trial. The primary efficacy variable was the mean change from baseline to endpoint (last treatment visit) in forced expiratory volume in one second (FEV1). Changes in FEV1 showed a statistically significant superiority (p<0.05) of MF DPI 200 and 400 microg b.i.d compared with the BUD Turbuhaler 400 microg b.i.d treatment. Significant superiority (p<0.05) was also seen in scores for several secondary efficacy variables when MF DPI was compared with BUD Turbuhaler treatment. MF DPI 200 microg b.i.d was comparable to MF DPI 400 microg b.i.d in therapeutic benefit. The incidence of oral candidiasis was no more than 3% in any group. All treatments were well tolerated. A total daily dose of 400 microg of mometasone furoate administered by dry powder inhaler provides a well-tolerated treatment for patients with moderate persistent asthma and results in a significantly greater improvement, when compared to a daily dose of 800 microg BUD Turbuhaler in the parameters measured in this study.

Previous
Back to top
Vol 16 Issue 5 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler
J Bousquet, A D'Urzo, J Hebert, CH Barraza, LP Boulet, R Suarez-Chacon, U Harnest, B Lundback, G Martinez Morales, MM Nieminen, KB Nolop, S Visser, BN Lutsky
European Respiratory Journal Nov 2000, 16 (5) 808-816;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler
J Bousquet, A D'Urzo, J Hebert, CH Barraza, LP Boulet, R Suarez-Chacon, U Harnest, B Lundback, G Martinez Morales, MM Nieminen, KB Nolop, S Visser, BN Lutsky
European Respiratory Journal Nov 2000, 16 (5) 808-816;
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Lung volume reduction surgery versus conservative treatment in severe emphysema
  • Inhaled isotonic alkaline versus saline solution and radioaerosol clearance in chronic cough
  • Dietary supplementation with fish oil rich in omega-3 polyunsaturated fatty acids in children with bronchial asthma
Show more Clinical Trial

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society